Global Rheumatoid Arthritis Drugs Market Drivers & Opportunities to 2023 - Featuring AbbVie, Amgen, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Merck, and More - ResearchAndMarkets.com

September 28, 2018

DUBLIN--(BUSINESS WIRE)--Sep 28, 2018--The “Global Rheumatoid Arthritis Drugs Market - Segmented by Type of Molecule, Drug Class, Sales Channel, and Geography - Growth, Trends, and Forecast (2018 - 2023)” report has been added to ResearchAndMarkets.com’s offering.

The global rheumatoid arthritis drugs market is expected to register a CAGR of 10.5% during the forecast period of 2018-2023.

Factors, such as the influx of new biopharmaceuticals, growing patient awareness of RA, and increasing prevalence of arthritis are expected to fuel the market’s growth, over the forecast period.

Owing to the rise in the adoption of sedentary lifestyle, the patient pool in Asia-Pacific is expected to witness healthy growth. Therefore, Asia-Pacific is expected to emerge as the fastest growing segment of the market studied. North America is expected to dominate.

Rise in the Prevalence of Arthritis

The major risk factors associated with the onset of rheumatoid arthritis are - genetics, environmental factors, hormones, and sedentary lifestyles. According to the estimates of the Centre for Disease Control and Prevention, during 2013-2015, an estimated 54.4 million US adults (about 22.7%) annually, were diagnosed with some form of arthritis, rheumatoid arthritis, gout, lupus, or fibromyalgia.

Other factors, such as growing geriatric population and increasing acceptance of biopharmaceuticals are expected to drive the growth of the market studied, over the forecast period.

Notable Developments in the Market

Sandoz, a Novartis division, announced that the European Commission (EC) has approved Zessly (infliximab) for use in Europe. AbbVie’s Upadacitinib demonstrated positive results as monotherapy in phase 3 rheumatoid arthritis study, meeting all primary and key secondary endpoints.

Key Topics Covered

1. Introduction

2. Research Methodology

3. Executive Summary

4. Key Inferences

5. Market Overview

6. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)

7. Market Segmentation

8. Competitive Landscape

9. Key Players

AbbVie Inc. Amgen Inc. Bayer AG Boehringer Ingelheim GmbH Bristol-Myers Squibb Company Celgene Corporation F. Hoffmann-La Roche AG Johnson & Johnson Services Inc. Merck & Co. Inc. Novartis AG

10. Future of the Market

For more information about this report visit https://www.researchandmarkets.com/research/f34jgq/global_rheumatoid?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180928005137/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Immune Disorders Drugs,Musculoskeletal Disorders Drugs



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 09/28/2018 05:47 AM/DISC: 09/28/2018 05:47 AM


Update hourly